RxDoctor Payments Data

Ian Dorward, MD

Neurological Surgery · Provo, UTNPI 1841417896

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.1%), speaking fees and royalties or licence payments — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Globus Medical at 38.7% of the total. Reporting peaked in 2022 at $31,393 and has fallen 74.3% since, to $8,082 in 2025. Among neurological surgery clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$104,005in general payments, 2019–2025

Across 126 payments — averaging $825.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$40K
  • Expanding Innovations, Inc.$37K
  • Orthofix Medical, Inc.$21K
  • Alphatec Spine, Inc$3K
  • Stryker$2K
  • Medtronic$223
  • plus $456 from 6 others
$196,856in research payments, 2019–2025

Across 16 payments — averaging $12,303 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medical Device Business Services, Inc.$187K
  • Orthofix Medical, Inc.$10K
$36,378in ownership & investment interests, 2019–2025

Across 5 payments — averaging $7275.58 each. An ownership or investment interest held by the physician or an immediate family member.

  • Expanding Innovations, Inc.$36K

What the payments were for

  • Royalty or licence$17,02916%
  • Consulting fees$44,78843%
  • Speaking & faculty fees$23,75023%
  • Travel & lodging$14,07814%
  • Food & beverage$4,3614%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$104,005 in reported general payments places this provider in the 90th percentile of 75 neurological surgery providers in Utah.

See all neurological surgery providers in Utah

Medicare billing

Part B allowed, 2024
$114,837
Medicare patients
106
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriparatide13$22,827
Tizanidine Hcl94$1,597
Cyclobenzaprine Hcl94$1,359
Oxycodone Hcl83$571
Gabapentin60$497
Mupirocin63$379
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$214
Tramadol Hcl16$69

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →